Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Netarsudil
Drug ID BADD_D02519
Description A Rho kinase inhibitor with norepinephrine transport inhibitory activity that reduces production of aqueous As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for the indication of reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Acting as both a rho kinase inhibitor and a norepinephrine transport inhibitor, Netarsudil is a novel glaucoma medication in that it specifically targets the conventional trabecular pathway of aqueous humour outflow to act as an inhibitor to the rho kinase and norepinephrine transporters found there as opposed to affecting protaglandin F2-alpha analog like mechanisms in the unconventional uveoscleral pathway that many other glaucoma medications demonstrate.
Indications and Usage Netarsudil is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension [FDA Label].
Marketing Status approved
ATC Code S01EX05
DrugBank ID DB13931
KEGG ID D11030
MeSH ID C000603944
PubChem ID 66599893
TTD Drug ID D04WYX
NDC Product Code 70727-497
UNII W6I5QDT7QI
Synonyms netarsudil | AR-13324
Chemical Information
Molecular Formula C28H27N3O3
CAS Registry Number 1254032-66-0
SMILES CC1=CC(=C(C=C1)C(=O)OCC2=CC=C(C=C2)C(CN)C(=O)NC3=CC4=C(C=C3)C=NC=C4)C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Anxiety19.06.02.0020.000365%
Blepharitis23.03.04.012; 06.04.04.0010.000365%Not Available
Blepharitis allergic23.03.04.030; 10.01.03.034; 06.04.04.0090.000365%Not Available
Conjunctival haemorrhage24.07.05.001; 06.07.01.0010.000365%Not Available
Corneal oedema06.04.02.0010.002558%Not Available
Death08.04.01.0010.001397%
Erythema23.03.06.0010.000365%Not Available
Eye allergy10.01.03.028; 06.04.05.0100.000365%Not Available
Eye discharge06.04.05.0010.000731%Not Available
Eye irritation06.04.05.0030.001279%Not Available
Eye pain06.08.03.0020.000365%
Eye swelling06.08.03.0030.000365%Not Available
Eyelid oedema06.04.04.004; 23.04.01.003; 10.01.05.0010.000365%Not Available
Hypersensitivity10.01.03.0030.000731%
Insomnia19.02.01.002; 17.15.03.0020.000365%
Instillation site pain12.07.01.008; 08.02.01.0080.000548%Not Available
Lacrimation increased06.08.02.0040.000365%
Ocular hyperaemia06.04.05.0040.000548%Not Available
Pruritus23.03.12.0010.000548%
Punctate keratitis06.04.02.0030.000365%Not Available
Urticaria23.04.02.001; 10.01.06.0010.000365%
Uveitis10.02.01.023; 06.04.03.0030.000365%
Vision blurred17.17.01.010; 06.02.06.0070.001698%
Visual acuity reduced17.17.01.011; 06.02.10.0120.002740%
Visual impairment06.02.10.0130.000731%Not Available
Foreign body sensation in eyes06.01.01.0060.000548%Not Available
Conjunctival hyperaemia06.04.01.0040.003837%Not Available
Eyelids pruritus23.03.12.005; 06.08.03.0070.000548%Not Available
Eye pruritus06.04.05.0060.000548%Not Available
Dacryostenosis acquired06.06.04.0030.002192%Not Available
The 1th Page    1 2    Next   Last    Total 2 Pages